Preferred Label : CDK4/6 Inhibitor TQB3616;
NCIt definition : An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types
4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration,
CDK4/6 inhibitor TQB3616 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation
of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase
transition and leads to cell cycle arrest. This suppresses DNA replication and decreases
tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated
in many tumor cell types and play a key role in the regulation of both cell cycle
progression from the G1-phase into the S-phase and tumor cell proliferation.;
Molecule name : TQB-3616; TQB 3616;
NCI Metathesaurus CUI : CL1405461;
Origin ID : C171344;
UMLS CUI : C5417854;
Semantic type(s)
- concept_is_in_subset
- has_target
